Antihistaminergics and inverse agonism: Potential therapeutic applications

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 26-32

  Monczor, Federico ^a,d   Fernandez, Natalia ^a,d   Fitzsimons, Carlos P ^b   Shayo, Carina ^c,d   Davio, Carlos ^a,d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^d Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

Adverse effect; Antihistaminergic; Histamine receptor; Inverse agonism

Indexed keywords

ALPRENOLOL; ANTIHISTAMINIC AGENT; ATROPINE; BISOPROLOL; CANNABINOID 1 RECEPTOR; CETIRIZINE; CIMETIDINE; G PROTEIN COUPLED H1 RECEPTOR; G PROTEIN COUPLED H2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; LORATADINE; METOPROLOL; NALOXONE; PHENTOLAMINE; PINDOLOL; PIRENZEPINE; PRAZOSIN; PROPRANOLOL; RANITIDINE; TIMOLOL; UNCLASSIFIED DRUG;

ALLERGY; ANGINA PECTORIS; CHONDRODYSPLASIA; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONGENITAL HYPERTHYROIDISM; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG USE; HAY FEVER; HEART ARRHYTHMIA; HEARTBURN; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INVERSE AGONISM; ISCHEMIC HEART DISEASE; JANSEN METAPHYSEAL CHONDRODYSPLASIA; LIGAND BINDING; LIVER METASTASIS; MELANOMA; MULTIPLE MYELOMA; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; STOMACH CANCER; THEORETICAL MODEL;

ADVERSE EFFECT; ANTIHISTAMINERGIC; HISTAMINE RECEPTOR; INVERSE AGONISM;

ANIMALS; DRUG INVERSE AGONISM; HISTAMINE ANTAGONISTS; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, HISTAMINE;

EID: 84885473848     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.027     Document Type: Review

References (90)

1. Andressen, K.W., Norum, J.H., Levy, F.O., Krobert, K.A., 2006. Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol. Pharmacol. 69, 207-215. (Pubitemid 43048907)
2. Arrang, J.M., Devaux, B., Chodkiewicz, J.P., Schwartz, J.C., 1988. H3-receptors control histamine release in human brain. J. Neurochem. 51, 105-108.
3. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M.C., Cesarman, E., 1997. Human herpesvirus kshv encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385, 347-350.
4. Bakker, R.A., Timmerman, H., Leurs, R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. In: Simons, F.E.R. (Ed.), Histamine and H1-antihistamines in allergic disease. 2002, pp. 27-64.
5. Bastepe, M., Raas-Rothschild, A., Silver, J., Weissman, I., Wientroub, S., Jüppner, H., Gillis, D., 2004. A form of Jansen's metaphyseal chondrodysplasia with limited metabolic and skeletal abnormalities is caused by a novel activating parathyroid hormone (PTH)/PTH-related peptide receptor mutation. J. Clin. Endocrinol. Metab. 89, 3595-3600. (Pubitemid 38951939)
6. Bindslev, N., 2004. A homotropic two-state model and auto-antagonism. BMC Pharmacol. 4, 11.
7. Black, J.W., Duncan, W.A., Durant, C.J., Ganellin, C.R., Parsons, E.M., 1972. Definition and antagonism of Histamine H2-receptors. Nature 236, 385-390.
8. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., 1997. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330-22339. (Pubitemid 27382869)
9. Brown, G.P., Pasternak, G.W., 1998. 3H-naloxone benzoylhydrazone binding in MOR-1-transfected chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding. J. Pharmacol. Exp. Ther. 286, 376-381. (Pubitemid 28318013)
10. Burgaud, J.L., Oudart, N., 1993. Effect of an histaminergic H3 agonist on the non-adrenergic non-cholinergic contraction in guinea-pig perfused bronchioles. J. Pharm. Pharmacol. 45, 955-958.
11. Burtin, C., Noirot, C., Scheinmann, P., Galoppin, L., Sabolovic, D., Bernard, P., 1988. Clinical improvement in advanced cancer disease after treatment combining Histamine and H2-antihistaminics (ranitidine or cimetidine). Eur. J. Cancer Clin. Oncol. 24, 161-167. (Pubitemid 18051180)
12. Chen, S., Lin, F., Xu, M., Hwa, J., Graham, R.M., 2000. Dominant-negative activity of an alpha(1b)-adrenergic receptor signal-inactivating point mutation. EMBO J. 19, 4265-4271. (Pubitemid 30623737)
13. Chidiac, P., 2002. Considerations in the evaluation of inverse agonism and protean agonism at G protein-coupled receptors. Methods Enzymol. 343, 3-16.
14. Clapham, J., Kilpatrick, G.J., 1992. Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br. J. Pharmacol. 107, 919-923.
15. Costa, T., Cotecchia, S., 2005. Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 26, 618-624. (Pubitemid 41636306)
16. Cricco, G., Davio, C., Bergoc, R., Rivera, E., 1993. Inhibition of tumor growth induced by Histamine: in vivo and in vitro studies. Inflamm. Res. 38, 75-78.
17. Davies, T.F., Ando, T., Lin, R., Tomer, Y., Latif, R., 2005. Thyrotropin receptor-associated diseases: from adenomata to graves disease. J. Clin. Invest. 115, 1972-1983. (Pubitemid 41134132)
18. Davio, C., Baldi, A., Mladovan, A., Cricco, G., Fitzsimons, C., Bergoc, R., Rivera, E., 1995. Expression of histamine receptors in different cell lines derived from mammary gland and human breast carcinomas. Inflamm. Res. 44 (Suppl. 1), S70-S71.
19. Davio, C., Mladovan, A., Lemos, B., Monczor, F., Shayo, C., Rivera, E., Baldi, A., 2002. H1 and H2 histamine receptors mediate the production of inositol phosphates but not cAMP in human breast epithelial cells. Inflamm. Res. 51, 1-7. (Pubitemid 34117366)
20. De Lean, A., Kilpatrick, B.F., Caron, M.G., 1982. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol. Pharmacol. 22, 290-297. (Pubitemid 12028825)
21. Delvalle, J., Wang, L., Gantz, I., Yamada, T., 1992. Characterization of H2 histamine receptor: linkage to both adenylate cyclase and [Ca2+]i signaling systems. Am. J. Physiol. 263, G967-972. (Pubitemid 23033288)
22. Dowling, M.R., Willets, J.M., Budd, D.C., Charlton, S.J., Nahorski, S.R., Challiss, R.A.J., 2006. A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J. Pharmacol. Exp. Ther. 317, 1134-1142. (Pubitemid 43764117)
23. Dryja, T.P., Berson, E.L., Rao, V.R., Oprian, D.D., 1993. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat. Genet. 4, 183-280.
24. el Battari, A., Martin, J.M., Luis, J., Pouzol, O., Secchi, J., Marvaldi, J., Pichon, J., 1988. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J. Biol. Chem. 263, 17685-17689. (Pubitemid 19029340)
25. Fitzsimons, C.P., Gompels, U.A., Verzijl, D., Vischer, H.F., Mattick, C., Leurs, R., Smit, M.J., 2006. Chemokine-directed trafficking of receptor stimulus to different G proteins: selective inducible and constitutive signaling by human herpesvirus 6-encoded chemokine receptor U51. Mol. Pharmacol. 69, 888-898. (Pubitemid 43363863)
26. Fitzsimons, C.P., Monczor, F., Fernández, N., Shayo, C., Davio, C., 2004. Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G proteincoupled form of the receptor and sequesters G protein. J. Biol. Chem. 279, 34431-34439. (Pubitemid 39318069)
27. Fitzsimons, C., Durán, H., Engel, N., Molinari, B., Rivera, E., 1999. Changes in H2 receptor expression and coupling during Ca2+-induced differentiation in mouse epidermal keratinocytes. Inflamm. Res. 48 (Suppl. 1), S73-S74. (Pubitemid 29192347)
28. Friedel, R.O., Schanberg, S.M., 1975. Effects of histamine on phospholipid metabolism of rat brain in vivo. J. Neurochem. 24, 819-820.
29. Georgieva, T., Devanathan, S., Stropova, D., Park, C.K., Salamon, Z., Tollin, G., Hruby, V.J., Roeske, W.R., Yamamura, H.I., Varga, E., 2008. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur. J. Pharmacol. 581, 19-29.
30. Gespach, C., Bawab, W., de Cremoux, P., Calvo, F., 1988. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 48, 5079-5083.
31. Hall, D.A., 2000. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423.
32. Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R., Haas, H.L., 1997. International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol. Rev. 49, 253-278. (Pubitemid 27414915)
33. Hokin, M.R., Hokin, L.E., 1953. Enzyme secretion and the incorporation of P32 into phospholipides of pancreas slices. J. Biol. Chem. 203, 967-977.
34. Imamura, M., Seyedi, N., Lander, H.M., Levi, R., 1995. Functional identification of histamine H3-receptors in the human heart. Circ. Res. 77, 206-210.
35. Ishikawa, S., Sperelakis, N., 1987. A novel class (H3) of histamine receptors on perivascular nerve terminals. Nature 327, 158-160. (Pubitemid 17062761)
36. Kaufman, D.W., Kelly, J.P., Rosenberg, L., Anderson, T.E., Mitchell, A.A., 2002. Recent patterns of medication use in the ambulatory adult population of the United States: the slone survey. JAMA 287, 337-344. (Pubitemid 34251967)
37. Keen, T.J., Inglehearn, C.F., Lester, D.H., Bashir, R., Jay, M., Bird, A.C., Jay, B., Bhattacharya, S.S., 1991. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 11, 199-205.
38. Kenakin, T., 1995. Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci. 16, 188-192.
39. Kenakin, T., 2002. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1, 103-110. (Pubitemid 41646517)
40. Kenakin, T., 2004. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2-11. (Pubitemid 38113879)
41. Kenakin, T., Onaran, O., 2002. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23, 275-280. (Pubitemid 34655733)
42. Korman, L.Y., Carney, D.N., Citron, M.L., Moody, T.W., 1986. Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung. Cancer Res. 46, 1214-1218. (Pubitemid 16048258)
43. Kroog, G.S., Jensen, R.T., Battey, J.F., 1995. Mammalian bombesin receptors. Med. Res. Rev. 15, 389-417.
44. Lee, T.W., Cotecchia, S., Milligan, G., 1997. Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1b-adrenoceptor by ligands that act as inverse agonists. Biochem J. 325 (Pt 3), 733-739.
45. Leff, P., 1995. The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97.
46. Leurs, R., Chazot, P.L., Shenton, F.C., Lim, H.D., de Esch, I.J.P., 2009. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J. Pharmacol. 157, 14-23.
47. Leurs, R., Church, M.K., Taglialatela, M., 2002. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy 32, 489-498. (Pubitemid 34429565)
48. MacEwan, D.J., Milligan, G., 1996. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol. Pharmacol. 50, 1479-1486.
49. Martin, M.W., Smith, M.M., Harden, T.K., 1984. Modulation of muscarinic choliner-gic receptor affinity for antagonists in rat heart. J. Pharmacol. Exp. Ther. 230, 424-430. (Pubitemid 14061623)
50. Maussang, D., Langemeijer, E., Fitzsimons, C.P., Stigter-van Walsum, M., Dijkman, R., Borg, M.K., Slinger, E., Schreiber, A., Michel, D., Tensen, C.P., van Dongen, G.A., Leurs, R., Smit, M.J., 2009. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res. 69, 2861-2869.
51. McLoughlin, D.J., Strange, P.G., 2000. Mechanisms of agonism and inverse agonism at serotonin 5-HT1a receptors. J. Neurochem. 74, 347-357. (Pubitemid 30012788)
52. Meye, F.J., Trezza, V., Vanderschuren, L.J.M.J., Ramakers, G.M.J., Adan, R.A.H., 2012. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol. Psychiatry.
53. Milligan, G., Bond, RA, Lee, M., 1995. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16, 10-13.
54. Molnar, E.L., Cricco, G., Martin, G., Darvas, Z., Hegyesi, H., Fitzsimons, C, Bergoc, R., Falus, A., Rivera, E., 2001. Histamine as a potential autocrine regulator of melanoma. Inflamm. Res. 50 (Suppl. 2), S102-S103. (Pubitemid 32452988)
55. Monczor, F., Fernandez, N., Legnazzi, B.L, Riveiro, M.E., Baldi, A., Shayo, C, Davio, C, 2003. Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. Mol. Pharmacol. 64, 512-520. (Pubitemid 36910016)
56. Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, CR., Schwartz, J.C, Arrang, J.M., 2000. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408, 860-864. (Pubitemid 32016096)
57. Nakaya, N., Tasaka, K., 1988. The influence of histamine on precursors of granulocytic leukocytes in murine bone marrow. Life Sci. 42, 999-1010. (Pubitemid 18065343)
58. Nielsen, HJ., 1991. Histamine and histamine type-2 receptor antagonists in psoriasis. Mech. Speculations Dan. Med. Bull. 38, 478-480.
59. Nielsen, HJ., 1996. Histamine-2 receptor antagonists as immunomodulators: new therapeutic views? Ann. Med. 28, 107-113. (Pubitemid 26120338)
60. Nielsen, H., Kikuchi, Y. Histamine H2-antagonists as potential adjuvant treatment of malignant disease. In: Garcia-Caballero, M., Brandes, L., Hosoda, S. (Eds.), Histamine in normal and cancer cell proliferation, advances in the bioscience. 1993, pp. 319-334.
61. Oda, T, Morikawa, N., Saito, Y., Masuho, Y, Matsumoto, S., 2000. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275, 36781-36786. (Pubitemid 32002087)
62. Onaran, H.O., Costa, T., 1997. Agonist efficacy and allosteric models of receptor action. Ann. NY Acad. Sci. 812, 98-115. (Pubitemid 27309688)
63. Osawa, S., Kajimura, M., Yamamoto, S., Ikuma, M., Mochizuki, C, Iwasaki, H., Hishida, A., Terakawa, S., 2005. Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G880-G889. (Pubitemid 41532581)
64. Pincus, D.W., DiCicco-Bloom, E.M., Black, I.B., 1990. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343, 564-567.
65. Raible, D.G., Lenahan, T., Fayvilevich, Y, Kosinski, R., Schulman, E.S., 1994. Pharmacologic characterization of a novel histamine receptor on human eosinophils. Am. J. Respir. Crit. Care Med. 149, 1506-1511. (Pubitemid 24175967)
66. Rivera, E., Davio, C, Cricco, G., Bergoc, R. Histamine regulation of tumor growth. Role of H1 and H2 receptors. In: Garcia-Caballero, M, Brandes, L, Hosoda, S (Eds.), Histamine in normal and cancer cell proliferation, advances in the bioscience. 1993, pp. 299-317.
67. Robertson, M.J., Dougall, I.G., Harper, D., McKechnie, K.C., Leff, P., 1994. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol. Sci. 15, 364-369. (Pubitemid 24325707)
68. Samama, P., Cotecchia, S., Costa, T, Lefkowitz, R.J., 1993. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636. (Pubitemid 23081571)
69. Schlicker, E., Fink, K., Detzner, M., Göthert, M., 1993. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J. Neural Transm. Gen. Sect. 93, 1-10. (Pubitemid 23235613)
70. Seifert, R., Wenzel-Seifert, K., 2002. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381-416. (Pubitemid 35251788)
71. Smit, M.J., Hoffmann, M., Timmerman, H., Leurs, R., 1999. Molecular properties and signaling pathways of the histamine H1 receptor. Clin. Exp. Allergy 29 (Suppl. 3), 19-28. (Pubitemid 29333328)
72. Smit, M.J., Leurs, R., Alewijnse, A.E., Blauw, J., Van Nieuw Amerongen, G.P., Van De Vrede, Y, Roovers, E., Timmerman, H., 1996. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl. Acad. Sci. USA 93, 6802-6807. (Pubitemid 26230391)
73. Smit, M.J., Timmerman, H., Alewijnse, A.E., Leurs, R., 1998. From histamine H2 receptor regulation to reclassification of H2 antagonists; inverse agonism as the basis for H2 receptor upregulation. Receptors Channels 5, 99-102.
74. Strange, P.G., 2002. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol. Sci. 23, 89-95. (Pubitemid 34119331)
75. Subramanian, N., Whitmore, W.L., Seidler, F.J., Slotkin, TA., 1981. Ontogeny of histaminergic neurotransmission in the rat brain: concomitant development of neuronal histamine, H-1 receptors, and H-1 receptor-mediated stimulation of phospholipid turnover. J. Neurochem. 36, 1137-1141. (Pubitemid 11157946)
76. Threlfell, S., Exley, R., Cragg, S.J., Greenfield, S.A., 2008. Constitutive histamine H2 receptor activity regulates serotonin release in the substantia nigra. J. Neurochem. 107, 745-755.
77. Tiligada, E., Kyriakidis, K., Chazot, P.L, Passani, M.B., 2011. Histamine pharmacology and new cns drug targets. CNS Neurosci. Ther. 17, 620-628.
78. Tubio, M.R., Fernandez, N., Fitzsimons, C.P., Copsel, S., Santiago, S., Shayo, C, Davio, C, Monczor, F., 2010. Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. J. Biol. Chem. 285, 14990-14998.
79. van der Werf, J.F., Timmerman, H., 1989. The histamine H3 receptor: a general presynaptic histaminergic regulatory system? Trends Pharmacol. Sci. 10, 159-162. (Pubitemid 19106308)
80. Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., 1994. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331, 1116-1121. (Pubitemid 24321216)
81. Wade, S.M., Lan, K., Moore, D.J., Neubig, R.R., 2001. Inverse agonist activity at the alpha(2a)-adrenergic receptor. Mol. Pharmacol. 59, 532-542. (Pubitemid 32179933)
82. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin, T.P., 1996a. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J. Theor. Biol. 181, 381-397. (Pubitemid 26333834)
83. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin, T.P., 1996b. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J. Theor. Biol. 178, 169-182. (Pubitemid 26118846)
84. Weiss, J.M., Morgan, P.H., Lutz, M.W., Kenakin, T.P., 1996c. The cubic ternary complex receptor-occupancy model. I. Model description. J. Theor. Biol. 178, 151-167. (Pubitemid 26118845)
85. Wellner-Kienitz, M.C., Bender, K., Meyer, T., Pott, L., 2003. Coupling to Gs and G(q/11) of histamine H2 receptors heterologously expressed in adult rat atrial myocytes. Biochim. Biophys. Acta. 1642, 67-77. (Pubitemid 37338280)
86. Westphal, R.S., Sanders-Bush, E., 1994. Reciprocal binding properties of 5-hydroxytryptamine type 2c receptor agonists and inverse agonists. Mol. Pharmacol. 46, 937-942. (Pubitemid 24364108)
87. Wilson, J., Lin, H., Fu, D., Javitch, J.A., Strange, P.G., 2001. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J. Neurochem. 77, 493-504. (Pubitemid 32298744)
88. Yap, Y., Camm, A. Potential cardiac toxicity of H1-antihistamines. In: Simos FER (Ed.), Histamine and h1-antihistamines in allergic disease, 2nd ed. 2002, pp. 389-419.
89. Zhu, Y., Michalovich, D., Wu, H., Tan, K.B., Dytko, G.M., Mannan, I.J., Boyce, R., Alston, J., Tierney, L.A., Li, X., 2001. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59, 434-441. (Pubitemid 32179920)
90. Zurier, R.B., Kozma, M., Sinnett-Smith, J., Rozengurt, E., 1988. Vasoactive intestinal peptide synergistically stimulates DNA synthesis in mouse 3t3 cells: role of cAMP, Ca2+, and protein kinase C. Exp. Cell. Res. 176, 155-161.